Furthermore, PRKDC downregulates the sensitivity of the HR+/HER2-type breast cancer cells (MCF-7 line) to chemotherapeutic agents in vitro and in xenograft mouse models, indicating that PRKDC is a prognostic biomarker of chemoresistance in breast cancer patients (Sun et al., 2017). This evidence concerns the gene ERBB2 and breast cancer.